Using pro-apoptotic drugs to improve treatments for pulmonary tuberculosis
Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-11125008
This study is looking at a new drug called navitoclax to see if it can help people with pulmonary tuberculosis (TB) by helping their bodies get rid of infected cells, which could lead to faster recovery and less damage to the lungs.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11125008 on ClinicalTrials.gov |
What this research studies
This research investigates the use of pro-apoptotic drugs, specifically navitoclax, to enhance the treatment of pulmonary tuberculosis (TB) by promoting the death of infected cells. The approach aims to reduce tissue damage and inflammation caused by TB, which can lead to chronic lung issues. By understanding how these drugs affect the immune response and bacterial clearance in the lungs, the research seeks to shorten TB treatment duration and prevent long-term lung damage. Patients may benefit from improved treatment outcomes and reduced side effects associated with traditional TB therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with pulmonary tuberculosis, particularly those experiencing complications from the disease.
Not a fit: Patients with non-pulmonary forms of tuberculosis or those who do not have active TB infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective TB treatments that reduce lung damage and improve long-term health outcomes for patients.
How similar studies have performed: Previous research has shown promising results with similar pro-apoptotic approaches in animal models, indicating potential for success in human applications.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JAIN, SANJAY — JOHNS HOPKINS UNIVERSITY
- Study coordinator: JAIN, SANJAY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.